NCT01782664 - A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

March 1, 2014

Study Completion Date

March 24, 2014

Conditions

Psoriasis

Interventions

DRUG

100 mg GSK2586184

100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

DRUG

200 mg GSK2586184

200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

DRUG

400 mg GSK2586184

400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

DRUG

Placebo

Placebo tablets to be taken twice daily with food for up to 84 days.

Trial Locations (15)

10117

GSK Investigational Site, Berlin

10827

GSK Investigational Site, Berlin

13507

GSK Investigational Site, Berlin

20354

GSK Investigational Site, Hamburg

45122

GSK Investigational Site, Essen

48149

GSK Investigational Site, Münster

48159

GSK Investigational Site, Münster

49074

GSK Investigational Site, Osnabrück

58453

GSK Investigational Site, Witten

70178

GSK Investigational Site, Stuttgart

86179

GSK Investigational Site, Augsburg

CF14 4XN

GSK Investigational Site, Cardiff

NW3 2QG

GSK Investigational Site, London

SE1 7EH

GSK Investigational Site, London

M6 8HD

GSK Investigational Site, Salford